WO2023067483 - PHARMACEUTICAL COMBINATIONS COMPRISING AN MDM2 INHIBITOR, A BCL2 INHIBITOR AND A HYPOMETHYLATING AGENT AND USES THEREOF FOR THE TREATMENT OF HAEMATOLOGICAL MALIGNANCIES
National phase entry is expected:
Publication Number
WO/2023/067483
Publication Date
27.04.2023
International Application No.
PCT/IB2022/059973
International Filing Date
18.10.2022
Title **
[English]
PHARMACEUTICAL COMBINATIONS COMPRISING AN MDM2 INHIBITOR, A BCL2 INHIBITOR AND A HYPOMETHYLATING AGENT AND USES THEREOF FOR THE TREATMENT OF HAEMATOLOGICAL MALIGNANCIES
[French]
COMBINAISONS PHARMACEUTIQUES COMPRENANT UN INHIBITEUR DE MDM2, UN INHIBITEUR DE BCL2 ET UN AGENT D'HYPOMÉTHYLATION ET LEURS UTILISATIONS POUR LE TRAITEMENT DE MALIGNITÉS HÉMATOLOGIQUES
Applicants **
NOVARTIS AG
Lichtstrasse 35
4056 Basel, CH
Inventors
FABRE, Claire
Novartis Pharma AG
Postfach
4002 Basel, CH
HALILOVIC, Ensar
Novartis Institutes for BioMedical Research, Inc.
250 Massachusetts Avenue
Cambridge, Massachusetts 02139, US
MENSSEN, Hans Dietrich Richard
Novartis Pharma AG
Postfach
4002 Basel, CH
PATHAK, Dhrubajyoti
Novartis Pharma AG
Postfach
4002 Basel, CH
Priority Data
63/257,148
19.10.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1783 | |
| EPO | Filing, Examination | 11020 | |
| Japan | Filing | 589 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 6310 |
Total: 20277 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The invention relates to a pharmaceutical combination comprising an MDM2 inhibitor, a BCL2 inhibitor and a hypomethylating agent. The present invention also relates to methods of treating haematological malignancies involving said combination.[French]
L'invention concerne une combinaison pharmaceutique comprenant un inhibiteur de MDM2, un inhibiteur de BCL2 et un agent d'hypométhylation. La présente invention concerne également des méthodes de traitement de malignités hématologiques impliquant ladite combinaison.